Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: The aim of the study was to compare the effectiveness of tirzepatide versus semaglutide in producing weight loss. Methods: tests. A random-effect model was used to calculate pooled "mean differences" (MDs). Study quality was estimated by Newcastle-Ottawa Quality Assessment Scale (NOS) and Cochrane risk of bias (RoB) version 2 tool, and publication bias was estimated through forest plots and the Egger's test. Results: A total of two randomized controlled trials (RCTs) and five retrospective cohorts were included in this MA. MA results showed that compared with the semaglutide, tirzepatide could produce significantly greater weight loss (MD = 4.23; 95% confidence interval (CI): 3.22 - 5.25; P < 0.01). Subgroup analysis showed a dose- and duration-dependent significantly superior therapeutic effect of tirzepatide (> 10 mg dose: MD = 6.50, 95% CI: 5.93 - 7.08, P < 0.01 vs. ≤ 10 mg: MD = 3.89, 95% CI: 2.12 - 5.65, P < 0.01) (> 6 months duration: MD = 5.00, 95% CI: 3.48 - 6.52, P < 0.01 vs. ≤ 6 months: MD = 3.50, 95% CI: 2.24 - 4.75, P < 0.01). The supremacy of tirzepatide was maintained in both types of studies: RCTs and retrospective cohorts. No publication bias was found through forest plots visually or Egger's test (Egger's regression asymmetry test P value 0.94). Study quality estimated by NOS revealed the quality of each study as "good" (≥ 7 points) and that estimated by the Cochrane RoB tool revealed "low" RoB. Conclusion: The pooled analysis provides evidence that tirzepatide is better than semaglutide in reducing body weight, regardless of study design. A dose-response relationship exists, and the weight loss magnitude increases with the dose or duration of tirzepatide. The studies that provide this evidence are of high quality and have a low RoB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, a critical dichotomy has emerged between the highly supervised environment of RCTs and the realities of routine clinical practice [4,5,16,17,18].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, real-world effectiveness lags trial efficacy, largely owing to high discontinuation rates.”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“The quality assessment of RCTs was performed using the Cochrane risk of bias (RoB) version 2 tool [14].”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 2×
“Several trials have reported significant weight loss caused by tirzepatide and semaglutide [2, 6-9].”
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · cited 1×
“Both GIP and GLP-1 are natural incretins and enhance insulin release and insulin sensitivity while reducing stomach clearing and digestive tract movements [3].”
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 3×
“Tirzepatide’s sensitivity for the GIPR is equivalent to endogenous GIP, but its sensitivity for the GLP-1R is five times less compared to endogenous GLP-1 [2].”
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.2525 · Cited by 334
Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2023) · doi:10.1101/2023.11.21.23298775 · Cited by 334
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324 · cited 1×
“These neurons contain both GLP-1R and GIPR [27].”
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1710 · Cited by 208
Central administration of GLP-1 and GIP decreases feeding in mice
NamKoong, C., Kim, M. S., Jang, B.-T., Lee, Y. H., Cho, Y.-M., & Choi, H. J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.031 · Cited by 114 · cited 1×
“The mechanism underpinning tirzepatide-induced weight loss may involve concurrent activation of GLP-1R/GIPR and the synergistic effects of the two GLP-1 and GIP at central nervous system (CNS) level [26].”
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024) · Diabetologia · doi:10.1007/s00125-024-06144-1 · Cited by 102 · cited 2×
“While several systematic review (SR) and MA have compared the efficacy of tirzepatide or semaglutide in reducing body weight, the included trials mostly compared either of these drugs with placebo or any other medication [22-24, 28, 29].”
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
Jamal, M. H., Alhashemi, M., Dsouza, C. L., Al-Hassani, S., Qasem, W., Almazeedi, S. M., & Al-Sabah, S. K. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07137-0 · Cited by 73
Cai, W., Zhang, R., Yao, Y., Wu, Q., & Zhang, J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1277113 · Cited by 66 · cited 3×
“While several systematic review (SR) and MA have compared the efficacy of tirzepatide or semaglutide in reducing body weight, the included trials mostly compared either of these drugs with placebo or any other medication [22-24, 28, 29].”
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01198-4 · Cited by 55 · cited 1×
“In the MA of Zhou et al [30], 14 RCTs compared tirzepatide with placebo or other medications.”
Małecki, M. T., Batterham, R. L., Sattar, N., Levine, J. A., Rodríguez, Á., Bergman, B. K., Wang, H., Ghimpeteanu, G., & Lee, C. J. (2023) · Diabetes Care · doi:10.2337/dc23-1135 · Cited by 52 · cited 1×
“Malecki et al reported that tirzepatide produced weight loss exceeding 15% in individuals with obesity [25].”
Anson, M., Henney, A. E., Broadwell, N., Zhao, S. S., Ibarburu, G. H., Lip, G. Y. H., Wilding, J. P. H., Cuthbertson, D. J., & Alam, U. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102777 · Cited by 44 · cited 1×
“In retrospective cohort studies, NOS revealed the quality of each study as “good” (≥ 7 points) (Table 3) [17-21].”
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
Jung, H. N., & Jung, C. H. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22012 · Cited by 42 · cited 1×
“Tirzepatide seems to be a promising and versatile addition in the FDA-approved drugs’ list of obesity management [4].”
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14940 · Cited by 40
Rochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., Itani, L., & El Ghoch, M. (2024) · Diseases · doi:10.3390/diseases12090204 · Cited by 34 · cited 1×
“While several systematic review (SR) and MA have compared the efficacy of tirzepatide or semaglutide in reducing body weight, the included trials mostly compared either of these drugs with placebo or any other medication [22-24, 28, 29].”
Lv, X., Wang, H., Chen, C., Zhao, Y., Li, K., Wang, Y., Wang, L., Fu, S., & Liu, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s443396 · Cited by 33 · cited 2×
“Lv et al [23] included eight RCTs in their MA of which six trials compared tirzepatide with a placebo or dulaglutide or insulin glargine or insulin degludec.”
Cheurfa, C., Tsokani, S., Kontouli, K., Boutron, I., & Chaimani, A. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02464-w · Cited by 22 · cited 1×
“Combining observational studies (retrospective cohort) and clinical trials in a single MA is permissible provided that the study design must be considered as a potential source of heterogeneity and subgroup analysis based on the study design must be conducted [11].”
Dutta, D., Kamrul-Hasan, A. B. M., Nagendra, L., & Bhattacharya, S. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.10 · Cited by 22 · cited 2×
“While several systematic review (SR) and MA have compared the efficacy of tirzepatide or semaglutide in reducing body weight, the included trials mostly compared either of these drugs with placebo or any other medication [22-24, 28, 29].”
736-P: Comparison of Semaglutide vs. Tirzepatide Therapy in Adults with Type 1 Diabetes (T1D)
GEBRE, H., Snell‐Bergeon, J. K., & Shah, V. N. (2024) · Diabetes · doi:10.2337/db24-736-p · Cited by 5 · cited 1×
“Tirzepatide retained its superiority by producing a higher weight loss % compared to semaglutide (minimum weight loss % MD of 4.00 by omitting Rodriguiez et al, 2024c [21] (12 months duration); maximum weight loss % MD of 4.48 by omitting Gebre et al, 2024a [19] (3 months duration)).”
Influential
Cited by
Asia at the Epicenter of the Global Cardiometabolic Shift
Khanna, S., Gan, G. C. H., Sindone, A. P., Tromp, J., Butler, J., Foo, R., Nerlekar, N., & Bhat, A. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.01.001 · Cited by 19
Mestres‐Arenas, A., Quesada‐López, T., Blasco‐Roset, A., Giralt, M., Villarroya, F., Planavila, A., & Peyrou, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119057 · Cited by 8
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“Randomized clinical trials (RCTs) have consistently demonstrated efficacy profiles previously unattainable with non-surgical interventions [4,7,8].”
Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison
Shil, K. K., Hira, A. D., Bakchi, S., Paul, S., Hossain, M., & Ghosh, D. K. (2025) · Cureus · doi:10.7759/cureus.98858 · Cited by 6
“The adverse event profile observed in our cohort mirrors prior reports, with gastrointestinal symptoms predominating and more frequently reported at higher tirzepatide doses [17,21].”
Gunasekaran, P., Inban, P., Agrawal, A., Thai, A., Aravazhi, P. S., Tariq, H., Prajjwal, P., & John, J. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102113 · Cited by 3
Metadata
- Authors
- Aamir, A. B., Latif, R., Alqoofi, J. F., Almarzoq, F. A., Fallatah, J. O., Hassan, G. A., & Saab, F. A. A. A. A.
- Affiliations
- Punjab Medical College (PK)
- Imam Abdulrahman Bin Faisal University (SA)
- Corresponding author
- Latif, Rabia
- Venue
- Journal of Clinical Medicine Research
- Publisher
- Elmer Press, Inc.
- Published
- 2025-05
- Volume
- 17
- Issue
- 5
- Pages
- 285-296
- ISSN
- 1918-3003 (ISSN-L)
- 1918-3011
- PMC
- PMC12151102
- OpenAlex
- W4410798625
- Cited by
- 19
- References
- 26
- Citations by year
- 2026: 17 · 2025: 2
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- tirzepatide, semaglutide, weight loss, obesity, GLP-1 receptor agonists, GIP receptor agonist, dose-response relationship, treatment duration, drug efficacy comparison, real-world data, retrospective cohort, randomized controlled trials, publication bias, risk of bias, Newcastle-Ottawa Scale, Cochrane risk of bias tool, Egger's test
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.